Circulating levels of PAI-1 and SERPINE1 4G/4G polymorphism are predictive of poor prognosis in HCC patients undergoing TACE

Rosa Divella, Antonella Daniele, Ines Abbate, Eufemia Savino, Porzia Casamassima, Giancarlo Sciortino, Giovanni Simone, Gennaro Gadaleta-Caldarola, Vito Fazio, Cosimo Damiano Gadaleta, Carlo Sabbà, Antonio Mazzocca

Research output: Contribution to journalArticlepeer-review

Abstract

Although several molecular markers have been proposed as prognostic of disease progression in Hepatocellular carcinoma (HCC), predictive markers of response to treatment are still unsatisfactory. Here, we propose a genetic polymorphism as a potential predictive factor of poor prognosis in HCC patients treated with transcatheter arterial chemoembolization (TACE). In particular,we showthat the guanosine insertion/deletion polymorphismin the promoter region of SERPINE1 gene at the−675 bp position, named 4G/4G, predicts poor prognosis in a cohort of 75 patientswith HCC undergoing TACE. By a combination of ELISA and SERPINE1 promoter study, we found that the presence of elevated plasma levels of plasminogen activator inhibitor-1 (PAI-1) in patients with 4G/4G genotype is significantly associated with reduced overall survival compared to patients with 5G/5G or 4G/5G genotype in HCC patients after TACE. Our analysis provided evidence that variation in SERPINE1 gene plays a role in defining the outcome in patients treatedwith TACE. In addition to a poor disease outcome, the 4G/4G variant represents an unfavorable predictive factor for response to chemotherapy as well.

Original languageEnglish
Pages (from-to)273-278
Number of pages6
JournalTranslational Oncology
Volume8
Issue number4
DOIs
Publication statusPublished - Aug 1 2015

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Circulating levels of PAI-1 and SERPINE1 4G/4G polymorphism are predictive of poor prognosis in HCC patients undergoing TACE'. Together they form a unique fingerprint.

Cite this